A federal advisory committee voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was tight. It is advisory only. The FDA has given no indication on whether it will adopt the suggestion. The move came after weeks of open hearings. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could reshape how the agency handles a part of the wellness market that is scaling quickly. Market observers are watching to see if the FDA picks up the plan. A representative for the regulator offered no firm timeline for a response. Wellness voices argue the change would broaden access to products that users favor. Skeptics warn that looser rules could invite misuse across a quickly growing market. The advisory vote only clears a path to a change, and the final call rests with the federal regulator.